Johnson & Johnson (JNJ) Investment Analysis
1. Executive Summary
Johnson & Johnson (JNJ) represents the quintessential archetype of a diversified healthcare conglomerate undergoing a profound structural pivot. Following the strategic separation of its Consumer Health business, Kenvue, in 2023, the organization has re-emerged as a streamlined "two-sector" entity focused exclusively on high-margin, high-growth opportunities in Innovative Medicine and MedTech.[1, 2] Headquartered in New Brunswick, New Jersey, the company leverages a global infrastructure to develop and commercialize products that address some of the most pervasive and complex health challenges across the human lifespan.[1, 3] In fiscal year 2025, which management characterized as a "catapult year," the company reported total sales of $94.2 billion, reflecting an operational growth rate of 5.3% despite significant headwinds from the loss of exclusivity (LOE) for its top-selling drug, Stelara.[4, 5, 6]
The primary mechanism for revenue generation at Johnson & Johnson is the development and commercialization of patented therapeutics and sophisticated medical devices. The Innovative Medicine segment, which contributed $60.4 billion in 2025, generates revenue through the sale of prescription medicines to a diverse array of customers, including pharmaceutical wholesalers, specialty distributors, hospitals, and government agencies.[6, 7, 8] The MedTech segment, generating $33.8 billion, operates through the sale of surgical instruments, cardiovascular intervention tools, and orthopedic systems directly to healthcare systems and ambulatory surgical centers.[6, 9, 10]
Johnson & Johnson’s core product portfolio is anchored by 28 platforms or brands that each generate more than $1 billion in annual revenue.[11, 12] In the pharmaceutical division, the "crown jewel" is Darzalex, a multiple myeloma therapy that achieved over $14 billion in sales in 2025, while the MedTech division is led by its globally dominant electrophysiology platform and the newly integrated high-growth franchises of Abiomed and Shockwave Medical.[5, 9, 13, 14] The primary customer types are institutional in nature, ranging from large-scale healthcare providers and academic medical centers to national health services and insurance payers who manage complex reimbursement landscapes.[1, 8, 15]
The most critical end markets for the company include oncology, immunology, neuroscience, and cardiovascular care. In these segments, customers choose Johnson & Johnson over competitors like Merck, Medtronic, or Boston Scientific due to a combination of clinical superiority, integrated technological ecosystems, and a reputation for stability codified in the company’s "Our Credo" philosophy.[8, 10, 14, 16] The company’s ability to provide end-to-end solutions—such as combining cardiac mapping software with therapeutic catheters—creates a level of stickiness and switching costs that few peers can replicate.[13, 17]
| Financial Metric (FY 2025) |
Value |
| Total Reported Sales |
\$94.19 Billion |
| Operational Sales Growth |
5.3\% |
| GAAP Net Earnings |
\$26.80 Billion |
| Adjusted Diluted EPS |
\$10.79 |
| Free Cash Flow |
\$19.7 Billion |
| R\&D Investment |
\$14.7 Billion |
| [4, 6, 7, 12] |
|
2. Business Drivers & Strategic Overview
Core Revenue Drivers and Product Detail
The fundamental engine of Johnson & Johnson’s current growth is its oncology franchise, which is projected to reach $50 billion in annual sales by 2030.[18, 19, 20] Within this segment, Darzalex (daratumumab) serves as the foundational therapy for multiple myeloma. Its mechanism as a CD38-directed monoclonal antibody has allowed it to become the backbone of both frontline and relapsed/refractory treatment regimens.[14, 21] The shift from intravenous administration to the subcutaneous Darzalex Faspro formulation has not only improved patient convenience but also extended the drug’s commercial runway by creating a more efficient healthcare workflow.[21, 22]
In immunology, the company is successfully managing the transition of its portfolio away from Stelara (ustekinumab), which faced a 41% sales decline in 2025 due to biosimilar entry and changes in Medicare Part D.[7, 21] The replacement driver is Tremfya (guselkumab), an IL-23 inhibitor that grew sales by 40% to $5.2 billion in 2025.[7, 21] Tremfya's expansion into indications like Crohn's disease and ulcerative colitis is critical for J&J to maintain its leading share in the autoimmune market.[2, 23]
MedTech revenue is increasingly driven by the Cardiovascular unit, which was the only medtech segment to grow by double digits (15.8%) in 2025.[9, 13] This growth is attributable to:
* Abiomed: Acquired for nearly $16.6 billion, providing the Impella heart pump, which is the world’s smallest heart pump used to support blood flow in patients with heart failure or undergoing high-risk percutaneous coronary interventions.[9, 13]
* Shockwave Medical: Acquired in 2024 for $13.1 billion, specializing in Intravascular Lithotripsy (IVL) technology, which uses sonic pressure waves to safely crack calcified plaque in heart and limb arteries.[5, 6, 24]
* Biosense Webster (Electrophysiology): The industry standard for treating atrial fibrillation (AFib) through the Carto 3 mapping system and specialized catheters.[13, 25]
Moat Analysis and Competitive Advantages
Johnson & Johnson’s economic moat is multi-layered and historically resilient, consisting of the following key attributes:
- Integrated Ecosystems (High Switching Costs): In the MedTech sector, the Carto 3 mapping system acts as the central "operating system" for the electrophysiology lab. Once a hospital invests in this platform and surgeons are trained on its proprietary software interface, the cost and logistical complexity of switching to a competitor like Medtronic’s or Boston Scientific’s mapping systems are prohibitive.[13, 17, 25]
- Intellectual Property (IP) and Biological Complexity: Unlike small-molecule drugs that face immediate 80-90% revenue erosion upon patent expiry, J&J’s portfolio is heavily weighted toward complex biologics and cell therapies like Carvykti.[19, 26] The manufacturing hurdles for CAR-T cell therapies—which involve extracting, modifying, and re-infusing a patient's own T-cells—create a "moat of complexity" that deters generic entry.[19, 23]
- Unrivaled Distribution and Scale: J&J’s presence in virtually every operating room and hospital pharmacy in the developed world allows it to utilize "bundled contracting" strategies.[8, 10] As an "anchor vendor," J&J can offer hospital systems comprehensive agreements covering everything from surgical sutures (Ethicon) to high-end robotic systems, providing a cost and service advantage that smaller, pure-play rivals cannot match.[8, 10, 24]
TAM and Market Opportunity Analysis
The Total Addressable Market (TAM) for Johnson & Johnson’s key growth drivers is expanding at a rate that outpaces broader GDP growth.
| Market Segment |
Projected TAM / Growth |
Credible Source Support |
| Global Oncology |
\$115 Billion by 2035 |
CAGR of 8.4\% (2026-2035) [27] |
| Cardiovascular MedTech |
\$157 Billion by 2034 |
CAGR of 8.6\% (2025-2034) [28] |
| Pulsed Field Ablation (PFA) |
\$16 Billion by 2033 |
CAGR of 32.7\% (2026-2033) [29] |
| Multiple Myeloma |
\$25 Billion by 2030 |
J\&J Segment Target [19] |
| Left Atrial Appendage Closure |
\$6 Billion by 2030 |
Industry Consensus [25] |
The PFA market represents perhaps the most significant near-term opportunity in MedTech. As AFib becomes more prevalent due to an aging population, the shift from traditional thermal ablation to PFA—which is five times faster and has a superior safety profile—is expected to drive a massive replacement cycle for existing hospital equipment.[17, 25, 29]
Competitive Landscape and Strategic Positioning
In Innovative Medicine, Johnson & Johnson is currently "gaining ground" in the oncology space. While Merck’s Keytruda remains the revenue leader in solid tumors, J&J’s dominance in blood cancers (Multiple Myeloma) is unchallenged, with the company treating 80% of MM patients at some point in their journey.[12, 14] J&J is "holding ground" in immunology by aggressively transitioning patients from Stelara to Tremfya, effectively mitigating the revenue vacuum typically associated with a patent cliff.[2, 30]
In MedTech, the landscape is more dynamic. Medtronic remains the world's largest medical device company by revenue ($33.5B), but J&J ($31.9B device-only revenue) is positioned to overtake them following Medtronic’s separation of its diabetes business.[8, 10] In the high-stakes PFA market, J&J’s Varipulse system is in an intense three-way race with Boston Scientific’s Farapulse and Medtronic’s PulseSelect.[25, 29] While Boston Scientific had an earlier launch in the U.S., J&J is using its 30-year expertise in mapping to position Varipulse Pro as a more "precise" and "workflow-efficient" alternative.[9, 17, 31]
Strategically, what matters most for investors is J&J’s shift toward a "pure-play" innovation model. By divesting Consumer Health and now moving to separate the slower-growth Orthopaedics (DePuy Synthes) unit by mid-2027, J&J is signaling a commitment to a higher risk-reward profile defined by biotech-like growth and medtech-like recurring revenue.[11, 13, 24]
3. Financial Performance & Valuation
2025 Financial Performance Summary
The fiscal year 2025 performance highlights a company that has successfully moved the "Stelara LOE into the rearview mirror".[11, 12] Despite Stelara's decline, total revenue reached $94.2 billion, beating various analyst expectations and demonstrating the power of J&J's diversified "billion-dollar platform" strategy.[2, 4]
- Net Earnings: $26.8 billion, a 90.6% increase over 2024, largely due to the absence of the prior year's one-time separation costs and litigation settlements.[4, 6]
- Adjusted Diluted EPS: $10.79, an 8.1% year-over-year increase, including a $0.10 dilutive impact from the acquisition of Halda Therapeutics.[4, 6, 11]
- Profitability: Adjusted pretax operating margins stood at 28.7% in Q4 2025, with management targeting an additional 50-basis point improvement in 2026.[32, 33]
Valuation Multiples and Market Context
As of April 2026, Johnson & Johnson trades at a valuation that reflects its perceived safety and the success of its recent guidance reset.
| Valuation Metric |
Current Value (April 2026) |
Historical / Industry Context |
| Share Price |
\$241.31 |
52-Week Range: \$141.50 - \$251.71 [34, 35] |
| Market Capitalization |
\$580.15 Billion |
Only healthcare company >\$100B revenue [15, 36] |
| Forward P/E (2026e) |
20.66x |
Industry Average: 14.2x; J\&J 5Y Avg: 15.6x [14, 37, 38] |
| P/E/G Ratio |
2.36x |
Reflects premium for defensive growth [36, 37] |
| Enterprise Value / EBITDA |
15.8x |
Based on \$30B+ Adjusted EBITDA estimates [38] |
| Dividend Yield |
2.15\% |
Markedly higher than broader market average [39] |
Financial Drivers and Valuation Logic
The valuation of Johnson & Johnson is no longer anchored by the "dividend-only" thesis of previous decades. Instead, the market is pricing in a structural re-rating based on:
- Accelerated Revenue Growth: The company has guided for a 5-7% operational sales CAGR through 2030, a significant acceleration from its 2.7% five-year historical average.[40, 41, 42] This is driven by the "catapult" in oncology and the "Shockwave-Abiomed" effect in MedTech.[4, 24]
- R&D Productivity: J&J invested $14.7 billion in R&D in 2025 (15.6% of revenue), ranking it among the top three pharmaceutical spenders globally.[7, 43] The "valuation bridge" depends on the company delivering 20 novel therapies and 50 product expansions by 2030.[40, 41]
- Capital Efficiency: Following the separation of Kenvue and the impending orthopaedics split, J&J is becoming a higher-margin business. Analysts project operating margins could normalize toward 34.5% by 2030, up from the current ~28-30% range, as lower-margin supply chain assets are shed.[33, 42]
- Free Cash Flow Durability: Generating ~$20 billion in FCF annually allows J&J to self-fund its $32 billion-plus M&A and R&D agenda while simultaneously maintaining its 63-year streak of dividend increases.[5, 12, 44]
The current Forward P/E of 20.6x is a "scarcity premium." In a volatile macroeconomic environment, investors are willing to pay more for J&J’s AAA-rated balance sheet and the "line of sight to double-digit growth" promised by CEO Joaquin Duato for the latter half of the decade.[3, 11, 12]
4. Risk Assessment & Macroeconomic Considerations
Company-Specific Execution Risks
The primary execution risk is the Stelara Erosion Trajectory. While J&J has successfully "delayed" some biosimilar entries through 2025, the full-scale launch of multiple competitors in 2026 could result in a sharper revenue decline than the projected "flat" Innovative Medicine performance.[26, 30] If biosimilar capture exceeds 80% in the first year—a typical trend for small molecules but less certain for biologics—J&J may face a multi-billion dollar revenue gap that Tremfya and Darzalex cannot immediately fill.[26, 45]
A second execution risk lies in the MedTech Robotic Launch (OTTAVA). J&J has invested billions into its robotic surgery platform to compete with Intuitive Surgical’s da Vinci system.[2, 10] The system was submitted for FDA review in late 2025, with a target clearance in 2026.[46, 47] Any delay or "Not Approvable" letter from the FDA would not only waste billions in R&D but also allow Intuitive to further solidify its monopoly in soft-tissue robotics.[2, 10]
Competitive Risks
The Pulsed Field Ablation (PFA) Battleground represents a significant competitive threat. In early 2026, Boston Scientific’s Farapulse system has already treated thousands of patients in the U.S., while J&J’s Varipulse Pro is only just launching in Europe.[25, 31] If surgeons find Farapulse’s "flower" catheter design more intuitive than J&J’s "variable-loop" design, J&J could lose its 30-year dominance in the electrophysiology market.[9, 25]
Regulatory and Legal Risks
- Talc Litigation (The "Black Whale"): J&J remains embroiled in nearly 100,000 talc-related lawsuits.[48] Despite trying to resolve these through a $9 billion Chapter 11 plan (the "Texas Two-Step"), courts have repeatedly rejected the strategy, citing J&J’s own financial strength as a reason it does not qualify for bankruptcy protection.[49, 50, 51] While a $9-11 billion settlement is widely anticipated by analysts, "nuclear verdicts" like the $1.5 billion Maryland jury award in 2026 suggest the ultimate liability could be significantly higher.[49, 50]
- Inflation Reduction Act (IRA) / Drug Pricing: Starting in 2026, the U.S. government will implement negotiated prices for top-selling drugs. J&J’s Xarelto and Imbruvica are among the first ten drugs selected.[26, 52] Management has already conceded "hundreds of millions" in lost profit through a "Most Favored Nation" pricing deal with the Trump administration to avoid even steeper tariffs.[15, 53]
Macroeconomic and Industry Structure Risks
- Tariff Exposure: J&J faces an estimated $500 million in tariff costs for 2026, a doubling from 2025.[11, 15] While a pharmaceutical exemption was reportedly secured, the MedTech division—which relies on global components for lasers, robotic arms, and sensors—remains highly vulnerable to trade war escalations.[2, 11, 15]
- China VBP (Volume-Based Procurement): The Chinese government’s aggressive central tendering for medical devices (specifically orthopaedics and surgical staples) has pressured J&J’s margins in the Asia-Pacific region.[24, 42] The planned separation of the Orthopaedics business is a direct strategic response to this structural industry shift.[9, 13]
Risk Hierarchy and Early Warning Signs
- What could go wrong: A systemic failure of the OTTAVA robotic launch combined with a higher-than-expected Stelara erosion rate.
- Early warning signs: MedTech operational growth dipping below 4% for two consecutive quarters, or a "mixed" verdict in a bellwether talc trial in Maine or Florida.[24, 48, 49]
- What would damage the long-term thesis: A global legal settlement for Talc exceeding $20 billion, which would severely impair J&J’s ability to conduct large-scale M&A (like the Shockwave deal) to fuel its 2030 growth targets.[12, 50]
5. 5-Year Scenario Analysis
The following scenarios analyze the potential total return for J&J shares through April 2031, using a base share price of $241.31 as of April 9, 2026.[35, 54]
Base Case (Probability: 55%)
In the base case, J&J successfully manages the "Stelara LOE in the rearview mirror" and executes on its $50 billion oncology target.
- Financial Assumptions: Revenue grows at a 6.1% CAGR, reaching ~$125.6 billion by 2031.[33, 55] Operating margins expand from ~28% to 32% as the Orthopaedics separation is finalized and high-margin oncology assets (Darzalex, Carvykti) scale.[33, 42] Share count is reduced by 1% annually through consistent buybacks.[56]
- Valuation Assumption: A 19.5x exit P/E multiple is applied, consistent with a stabilized, high-growth healthcare pure-play.[55]
- Bridge to Valuation: $125.6B Revenue x 32% Op Margin = ~$40B Operating Profit. After tax and interest, Adjusted Net Earnings per share reach ~$14.75.
- 5-Year Outcome: Projected share price of $288.00.[33, 55]
High Case (Probability: 25%)
The high case assumes J&J captures a dominant share of the PFA market and the OTTAVA robot achieves "best-in-class" status.
- Financial Assumptions: Revenue growth accelerates to 7.5% CAGR as Carvykti moves into second-line treatment and Milvexian (the next-gen anticoagulant) becomes a multi-billion dollar blockbuster.[19, 26] Operating margins reach 34.5% due to an extraordinary mix shift toward Innovative Medicine.[33, 42]
- Valuation Assumption: An exit P/E multiple of 22.0x, as a global talc settlement of <$8 billion removes the legal discount.[50]
- Bridge to Valuation: Higher revenue and margin expansion lead to Adjusted EPS of ~$16.50.
- 5-Year Outcome: Projected share price of $363.00.
Low Case (Probability: 20%)
The low case is defined by "catastrophic legal liability" and pipeline failure.
- Financial Assumptions: Revenue growth slows to 3.5% CAGR as PFA competition from Boston Scientific and Medtronic erodes J&J’s market share.[9, 25] Stelara erosion is faster than expected, and the IRA impacts the entire immunology portfolio. Operating margins compress to 26% due to sustained legal expenses and tariff headwinds.[11, 42]
- Valuation Assumption: A 14.0x exit P/E multiple, reflecting a "no-growth" or "high-risk" conglomerate discount.
- Bridge to Valuation: Adjusted EPS stagnates at ~$11.50 (near 2026 levels).
- 5-Year Outcome: Projected share price of $161.00.
Scenario Summary Table
| Scenario |
Year 5 Revenue |
Margin Assumption |
Exit P/E Multiple |
Implied Share Price |
5-Year Total Return* |
Probability |
| High Case |
\$135 Billion |
34.5\% (Op) |
22.0x |
\$363.00 |
~65.5\% |
25\% |
| Base Case |
\$125.6 Billion |
32.0\% (Op) |
19.5x |
\$288.00 |
~31.8\% |
55\% |
| Low Case |
\$110 Billion |
26.0\% (Op) |
14.0x |
\$161.00 |
-26.5\% |
20\% |
| Weighted |
\$124.8 Billion |
31.4\% |
19.0x |
$281.35 |
~28.9\% |
100\% |
| *Total return assumes dividend reinvestment. |
|
|
|
|
|
|
DEFENSIVE GROWTH MACHINE
6. Qualitative Scorecard
| Metric |
Score (1-10) |
Narrative |
| Management Alignment |
9 |
CEO Joaquin Duato is required to hold 12x his base salary in stock; other executive committee members must hold 6x, ensuring deep alignment with long-term shareholders.[57] |
| Revenue Quality |
9 |
Exceptionally high; 28 different platforms generate >\$1B in revenue, protecting the company from single-drug failures.[11, 12] |
| Market Position |
9 |
Dominant in Multiple Myeloma (#1) and Electrophysiology (#1); however, facing a "slugfest" in the new PFA and robotic markets.[9, 12, 14] |
| Growth Outlook |
8 |
The "5-7% CAGR" target is credible given the \$14.7B R\&D engine and the Shockwave/Abiomed integrations.[7, 40, 41] |
| Financial Health |
10 |
AAA-rated balance sheet with \$19.7B in 2025 Free Cash Flow; provides "resilience and durability" to weather any macro storm.[6, 11, 12] |
| Business Viability |
7 |
High durability, but the talc litigation is a "perennial choke point" that consumes management bandwidth and legal capital.[48, 50] |
| Capital Allocation |
8 |
Strong discipline; successfully pivoting away from Consumer and Orthopaedics toward high-growth MedTech and Pharma.[9, 13, 24] |
| Analyst Sentiment |
7 |
"Moderate Buy" consensus; 19 analysts are split between those cheering the 2026 guidance and those wary of PFA competition.[36, 58] |
| Profitability |
9 |
Consistently industry-leading; 28.7% adjusted pretax margins with a clear path to expansion post-separation.[32, 33] |
| Track Record |
10 |
63 years of consecutive dividend increases; a history of "experimenting with new ideas" as codified in the Credo.[7, 16, 39] |
| OVERALL SCORE |
8.6 |
Institutional-grade compounding asset. |
Note: This scorecard does not constitute financial advice or a recommendation.
STABLE COMPOUNDING TITAN
7. Conclusion & Investment Thesis
Johnson & Johnson’s transformation from a diversified healthcare "supermarket" into a focused innovation powerhouse is largely complete. The 2025 performance data serves as a compelling proof-of-concept for the new corporate structure, demonstrating that the company can absorb the loss of a $10 billion blockbuster like Stelara while still achieving 6% revenue growth.[2, 4, 21] The investment thesis for the next five years is predicated on the "Oncology-Cardiovascular Double-Engine": oncology is poised to deliver $50 billion in sales by 2030, while the cardiovascular unit (Abiomed, Shockwave, EP) provides a recurring, high-margin revenue stream that mimics the best of the technology sector.[9, 12, 13, 18]
Key catalysts for the upcoming 12-24 months include the clinical readout of the OTTAVA robotic system, the accelerated European rollout of Varipulse Pro, and a potential resolution of the Talc MDL.[17, 31, 47, 49] While the risks of litigation and intensifying competition in the PFA market are real, J&J’s AAA-rated balance sheet and its disciplined capital allocation strategy provide a margin of safety that few global peers can match.[6, 12, 25]
Note: This report does not provide financial advice or investment recommendations.
DIVERSIFIED INNOVATION ARBITRAGE
8. Technical Analysis, Price Action & Short-Term Outlook
Johnson & Johnson (JNJ) is currently exhibiting a "consolidation-to-bullish" technical profile. As of April 9, 2026, the stock trades at $241.31, almost exactly aligned with its 200-day moving average of $241.37.[35, 59] The stock has traded in a 52-week range of $141.50 to $251.71, with the recent 38% six-month rally reflecting a re-rating tied to the robust 2026 guidance.[33, 34] The short-term outlook is neutral to positive; investors are awaiting the Q1 2026 earnings release on April 14, where a projected EPS of $2.68 and revenue of $23.6 billion could act as a breakout catalyst if margins exceed the 29% threshold.[1, 36, 37]
CONSOLIDATING NEAR RESISTANCE
- Johnson & Johnson Q1 2026 Earnings Report - MarketBeat, https://www.marketbeat.com/earnings/reports/2026-4-14-johnson-johnson-stock/
- Johnson & Johnson Clears the Patent Cliff as 2026 Guidance Resets the Narrative, https://www.investing.com/analysis/johnson--johnson-clears-the-patent-cliff-as-2026-guidance-resets-the-narrative-200673620
- What you need to know about Johnson & Johnson's fourth-quarter and full-year 2025 earnings report, https://www.jnj.com/latest-news/2025-fourth-quarter-and-full-year-earnings
- Johnson & Johnson reports Q4 and Full-Year 2025 results, https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-reports-Q4-and-Full-Year-2025-results/default.aspx
- JNJ-Earnings-Presentation-Q4-2025-Final.pdf, https://s203.q4cdn.com/636242992/files/doc_financials/2025/q4/JNJ-Earnings-Presentation-Q4-2025-Final.pdf
- Johnson & Johnson reports Q4 and Full-Year 2025 results, https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q4-and-full-year-2025-results
- Johnson & Johnson | 10-K: FY2025 Annual Report - moomoo, https://news.moomoo.com/notice/306470628/johnson-johnson-10-k-fy2025-annual-report
- Biggest MedTech Companies 2026 - iData Research, https://idataresearch.com/news/biggest-medtech-companies/
- J&J's cardiovascular business boosts medtech growth in 2025-媒体中心-China International Medical Devices Exhibition, http://www.c-medfair.com/en/m/news_show.asp?id=777
- Top Medical Device Companies in 2026: Revenue Rankings, Market Share, and Industry Trends | MedDeviceGuide, https://meddeviceguide.com/blog/top-medical-device-companies-2026-revenue-rankings-guide
- Johnson & Johnson (JNJ) Earnings Call Transcript | The Motley Fool, https://www.fool.com/earnings/call-transcripts/2026/01/21/johnson-johnson-jnj-earnings-call-transcript/
- EDITED TRANSCRIPT - JNJ.N - Q4 2025 Johnson & Johnson Earnings Call EVENT DATE/TIME: JANUARY 21, 2026 / 1:30PM GMT, https://s203.q4cdn.com/636242992/files/doc_financials/2025/q4/JNJ-USQ_Transcript_2026-01-21.pdf
- J&J's cardiovascular business boosts medtech growth in 2025, https://www.medtechdive.com/news/jnj-q4-full-year-earnings-cardiovascular/810121/
- Is Johnson & Johnson Able to Maintain Its Strong Double-Digit Growth in Oncology? - Bitget, https://www.bitget.com/news/detail/12560605219506
- Cancer drugs fuel J&J's sales growth and upbeat forecast - FirstWord Pharma, https://firstwordpharma.com/story/7073177
- 2026 JNJ Proxy - Johnson & Johnson, https://www.jnj.com/download/johnson-johnson-2026-proxy.pdf
- Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe, https://www.jnj.com/media-center/press-releases/johnson-johnson-advances-pulsed-field-ablation-portfolio-with-the-launch-of-varipulse-pro-in-europe
- J&J eyes $100B in sales amid gains for cancer, immune drugs - BioPharma Dive, https://www.biopharmadive.com/news/johnson-johnson-2025-earnings-sales-cancer-immune-drugs/810097/
- JPM26: J&J reveals oncology strategy - Pharmaceutical Technology, https://www.pharmaceutical-technology.com/analyst-comment/jpm26-jj-reveals-oncology-strategy/
- J&J Raises 2025 Guidance, Eyes $50B Oncology - NiftyTrader, https://www.niftytrader.in/markets/jnj-q2-2025-guidance-oncology-growth/
- Led by Darzalex surge, J&J expects revenue to reach $100B in 2026 - Fierce Pharma, https://www.fiercepharma.com/pharma/led-darzalex-surge-jj-expects-revenue-reach-100b-2026
- Rare disease drug sales to surge past $400B by 2032 despite FDA volatility: Evaluate report, https://www.fiercepharma.com/pharma/rare-disease-drug-sales-surge-past-400b-2032-despite-fda-volatility-evaluate-report
- J&J Targets $50B Oncology Sales By 2030: Updated - BioSpace, https://www.biospace.com/business/j-j-raises-2025-outlook-as-oncology-and-neuroscience-drive-q2-growth
- What's Powering J&J's MedTech Growth Ahead of Q4 Release? - Finviz, https://finviz.com/news/274724/whats-powering-jjs-medtech-growth-ahead-of-q4-release
- J&J launches enhanced PFA device in Europe - MedTech Dive, https://www.medtechdive.com/news/Johnson-jnj-varipulse-pro-pfa-pulsed-field-ablation-ce-mark/816836/
- Johnson & Johnson 2026 Outlook: Patent Cliffs, Pipeline Catalysts & Competitive Intelligence | SyneticX, https://www.syneticx.com/blog/jnj.html
- Blockbuster Oncology Brands Market Size to Reach USD 115.06 Billion by 2035, https://www.novaoneadvisor.com/report/blockbuster-oncology-brands-market
- Cardiovascular Medtech Market Size, Share and Forecast 2034, https://www.zionmarketresearch.com/report/cardiovascular-medtech-market
- Pulsed Field Ablation Market Share & Opportunities 2026-2033, https://www.coherentmarketinsights.com/industry-reports/pulsed-field-ablation-market
- How Big Pharma is navigating a $300 billion patent cliff | PharmaVoice, https://www.pharmavoice.com/news/big-pharma-navigating-patent-cliff-300-billion-jnj-merck-abbvie/810915/
- Johnson And Johnson PFA Launch In Europe Puts MedTech In Focus - Simply Wall St News, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson/news/johnson-and-johnson-pfa-launch-in-europe-puts-medtech-in-foc
- JNJ Q4-2025 Earnings Call - Alpha Spread, https://www.alphaspread.com/security/nyse/jnj/investor-relations/earnings-call/q4-2025
- Johnson & Johnson Has Rallied 38% in the Last 6 Months. Here's Where the Stock Could Head in 2026 - TIKR.com, https://www.tikr.com/blog/johnson-johnson-has-rallied-38-in-the-last-6-months-heres-where-the-stock-could-head-in-2026
- Stock info | Johnson & Johnson, https://www.investor.jnj.com/stock-info/default.aspx
- Johnson & Johnson - 64 Year Stock Price History | JNJ - Macrotrends, https://www.macrotrends.net/stocks/charts/JNJ/johnson-johnson/stock-price-history
- Johnson & Johnson (JNJ) Expected to Announce Earnings on Tuesday - MarketBeat, https://www.marketbeat.com/instant-alerts/johnson-johnson-jnj-expected-to-announce-earnings-on-tuesday-2026-04-07/
- Johnson & Johnson (JNJ) Increases Yet Falls Behind Market: What Investors Need to Know - April 8, 2026 - Zacks Investment Research, https://www.zacks.com/stock/news/2896866/johnson-johnson-jnj-increases-yet-falls-behind-market-what-investors-need-to-know
- Johnson & Johnson Stock | Price, Dividend & Forecast 2026 | JNJ - Eulerpool, https://eulerpool.com/stock/Johnson-Johnson-Stock-US4781601046
- Johnson & Johnson (JNJ) Dividend Date & History - Koyfin, https://www.koyfin.com/company/jnj/dividends/
- Johnson & Johnson Announces Key Drivers for Long-Term Competitive Growth at Enterprise Business Review | Nasdaq, https://www.nasdaq.com/press-release/johnson-johnson-announces-key-drivers-for-long-term-competitive-growth-at-enterprise
- Johnson & Johnson Announces Key Drivers for Long-Term Competitive Growth at Enterprise Business Review, https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-key-drivers-for-long-term-competitive-growth-at-enterprise-business-review
- Johnson & Johnson Stock: 2026 Outlook After 50% Gains - TIKR.com, https://www.tikr.com/blog/johnson-johnson-stock-2026-outlook-after-50-gains
- Top 10 pharma R&D budgets in 2025 - Fierce Biotech, https://www.fiercebiotech.com/special-reports/top-10-pharma-rd-budgets-2025
- Stock info - Dividend history - investor.jnj.com, https://www.investor.jnj.com/stock-info/dividend-history/default.aspx
- The Patent Cliff Panic: A Pain Point Every Pharma Investor Faces - DrugPatentWatch, https://www.drugpatentwatch.com/blog/the-patent-cliff-panic-a-pain-point-every-pharma-investor-faces/
- J&J grows MedTech sales, eyes robotic system launch - Becker's Hospital Review, https://www.beckershospitalreview.com/supply-chain/jj-grows-medtech-sales-eyes-robotic-system-launch/
- Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration, https://www.jnj.com/media-center/press-releases/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration
- Johnson & Johnson Talcum Powder Lawsuit Update [April 2026] - TorHoerman Law, https://www.torhoermanlaw.com/johnson-and-johnson-talcum-powder-lawsuit/
- Talcum Powder Lawsuit Update | 2026 Status & Settlements - LawFirm.com, https://www.lawfirm.com/product-liability/talcum-powder/lawsuit-updates/
- Talcum Powder Settlements - Verdicts & Payouts (April 2026) - Drugwatch.com, https://www.drugwatch.com/talcum-powder/settlements/
- Talcum Powder Lawsuit | April 2026 J&J Litigation Updates - Motley Rice, https://www.motleyrice.com/toxic-exposure/talcum-powder-lawsuit
- Kill the Patent Cliff: How to Turn a $400 Billion Revenue Loss into a Competitive Edge, https://www.drugpatentwatch.com/blog/kill-the-patent-cliff-how-to-turn-a-400-billion-revenue-loss-into-a-competitive-edge/
- Johnson & Johnson Forecasts Strong 2026 Profit and Revenue After Beating Q4 Estimates - Alpha Spread, https://www.alphaspread.com/market-news/earnings/johnson-johnson-forecasts-strong-2026-profit-and-revenue-after-beating-q4-estimates
- J&J Stock Price History - Investing.com, https://www.investing.com/equities/johnson-johnson-historical-data
- Johnson & Johnson Stock in 2026: Can It Continue its 55% Rally? - TIKR.com, https://www.tikr.com/blog/johnson-johnson-stock-in-2026-can-it-continue-its-55-rally
- Johnson & Johnson Share Dividends | JNJ | US4781601046 - Fidelity International, https://www.fidelity.co.uk/factsheet-data/factsheet/US4781601046-johnson--johnson/dividends/1000
- Stock Ownership Guidelines for Directors and Executive Officers, https://www.jnj.com/corporate-governance/stock-ownership-guidelines-for-directors-and-executive-officers
- JNJ Stock Forecast: Analyst Ratings, Predictions & Price Target 2026 - Public Investing, https://public.com/stocks/jnj/forecast-price-target
- JNJ Technical Analysis, RSI and Moving Averages - Investing.com, https://www.investing.com/equities/johnson-johnson-technical